Screener
Ionis Pharmaceuticals IONS Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of deferred contract revenue | 73,837 | 73,761 |
| Other current liabilities | 25,149 | 22,738 |
| Total current liabilities | 315,638 | 781,567 |
| Long-term deferred contract revenue | 63,030 | 92,001 |
| 0 percent convertible senior notes due 2030, net | 753,356 | 751,495 |
| 1.75 percent convertible senior notes due 2028, net | 569,255 | 567,830 |
| Liability related to sale of future royalties, net | 562,574 | 551,353 |
| Long-term lease liabilities | 262,476 | 262,383 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's contract liabilities?
- Ionis Pharmaceuticals (IONS) reported contract liabilities of $63.03M in Q2 2026.
- How has Ionis Pharmaceuticals's contract liabilities changed year-over-year?
- Ionis Pharmaceuticals's contract liabilities decreased by 49.6% year-over-year, from $125.1M to $63.03M.
- What is the long-term trend for Ionis Pharmaceuticals's contract liabilities?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's contract liabilities has grown at a -26.3% compound annual growth rate (CAGR), from $424.05M to $92M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Ionis Pharmaceuticals's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude